Issue release date: 12.11.2024
2Marmara University, Institute of Health Sciences, Department of Pediatric Allergy-Immunology, Istanbul, Turkey
3University of Health Sciences, Center for Stem Cell and Gene Therapy Research and Practice, Istanbul, Turkey
4Istanbul Rumeli University, Corlu Reyap Hospital, Department of Neurosurgery, Istanbul, Turkey
5Istinye University, Faculty of Medicine, Department of Histology and Embryology, Istanbul, Turkey
6Liv Hospital, Center for Regenerative Medicine and Stem Cell Research & Manufacturing (LivMedCell), Istanbul, Turkey
7Istinye University, Center for Stem Cell and Tissue Engineering Research and Practice, Istanbul, Turkey DOI : 10.5137/1019-5149.JTN.31732-20.1 AIM: To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies.
MATERIAL and METHODS: This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago. The participant received six doses of intrathecal, intramuscular, and intravenous transplantation of Wharton?s jellv-derived mesenchymal stem cells (WJ-MSCs) at a goal dose of 1xl06 / kg respectively for each route of administration for six months.
RESULTS: No important negative effects were reported. The patients? speech, cognitive, memory and fine motor skills were improved. The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG).
CONCLUSION: SCT can have a promising future as a medical approach in recurrent TBI.
Keywords : Stem cell, Brain injury, Umbilical cord, Transplantation